Cboe UK CHF

Molecular Partners AG (MOLNZ.XC)

Compare
4.7100 -0.0350 (-0.74%)
At close: December 19 at 3:21:12 PM GMT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for MOLNZ.XC

Recent News: MOLNZ.XC

View More
Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January

Molecular Partners to Present at JP Morgan Healthcare Conference and Baader Helvea Swiss Equities Conference in January
GlobeNewswire 2 days ago
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet

Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet
Zacks 6 days ago
Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024

Molecular Partners Presents Clinical Data Supporting its Ongoing MP0533 Study and Preclinical Data on Next-Gen Conditioning Agent MP0621 at ASH 2024
GlobeNewswire 11 days ago
Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners Presents Preclinical Proof-of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024
GlobeNewswire last month
Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition

Molecular Partners Announces Upcoming Poster Presentations at the 65th ASH Annual Meeting and Exposition
GlobeNewswire last month
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going

Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
GlobeNewswire last month
Molecular Partners Announces Pricing of $20 Million Underwritten Offering

Molecular Partners Announces Pricing of $20 Million Underwritten Offering
GlobeNewswire last month
Molecular Partners Expands Radio-DARPin Collaboration

Molecular Partners Expands Radio-DARPin Collaboration
TipRanks last month
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics

Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
GlobeNewswire last month
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024

Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
GlobeNewswire last month
Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting

Molecular Partners Announces upcoming poster presentations at the 2024 SITC Annual Meeting
GlobeNewswire 2 months ago
View More